Objective: Epidemiologic studies suggest that vitamin D status plays a role in glycaemic control in patients with type 2 diabetes. However, intervention studies yielded inconsistent results. The aim of this study is to systematically review the effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes. Methods: Systematic review and meta-analysis. We searched Medline, Embase and the Cochrane Library for RCTs examining the effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes. A random-effects model meta-analysis was performed to obtain a summarized outcome of vitamin D supplementation on HbA 1c , fasting glucose and homeostasis model assessment -insulin resistance (HOMA-IR). Results: Twenty-three RCTs were included in this systematic review representing a total of 1797 patients with type 2 diabetes. Mean (± s.d.) change in serum 25-hydroxyvitamin D varied from 1.8 ± 10.2 nmol/L to 80.1 ± 54.0 nmol/L. Nineteen studies included HbA 1c as outcome variable. Combining these studies no significant effect in change of HbA 1c was seen after vitamin D intervention compared with placebo. A significant effect of vitamin D supplementation was seen on fasting glucose in a subgroup of studies (n = 4) with a mean baseline HbA 1c ≥ 8% (64 mmol/mol) (standardized difference in means: 0.36; 95% CI: 0.12-0.61, P = 0.003). Conclusions: Current evidence of RCTs does not support short-term vitamin D supplementation in a heterogeneous population with type 2 diabetes. However, in patients with poorly controlled diabetes, a favourable effect of vitamin D is seen on fasting glucose.
Introduction
Vitamin D is a key factor for the maintenance of calcium and bone homeostasis. Over the past decade, vitamin D has attracted substantial interest due to its extra-skeletal roles in various disease conditions, including diabetes mellitus (1) . This interest has arisen due to the identification that most cells, including the pancreatic beta-cells, contain the vitamin D receptor (VDR). Most of these cells also have the capability to produce the biologically active form of vitamin D: 1,25-dihydroxyvitamin D for paracrine functions (1, 2, 3) . Furthermore, vitamin D is known to have immuno-modulatory and anti-inflammatory effects, which could improve peripheral insulin resistance by altering low-grade chronic inflammation that has been implicated in insulin resistance in type 2 diabetes mellitus (3, 4, 5) .
Observational studies have demonstrated a link between vitamin D deficiency and the onset of and progression of type 2 diabetes (6, 7, 8, 9) . Furthermore, low vitamin D status is associated with future macrovascular events in patients with type 2 diabetes mellitus (10) . This association may be the result of the link between vitamin D status and renin-angiotensin system (11) , endothelial function (12) , blood pressure (13) or chronic inflammation (4) .
A recent meta-analysis performed in 2012 by George et al. (14) has demonstrated a weak positive effect of vitamin D supplementation on fasting glucose and insulin resistance in patients with type 2 diabetes mellitus. However, overall, the authors concluded that there was insufficient evidence of a beneficial effect to recommend vitamin D supplementation as a means of improving glycaemic control in patients with type 2 diabetes, impaired fasting glucose or normal glucose tolerance. Inconsistency in these results may be due to the different study populations (normal glucose tolerance, impaired glucose tolerance and type 2 diabetes), small sample sizes and different dosage regimes of vitamin D supplementation. Additionally, a meta-analysis published by Seida et al. in 2014 , which included RCTs among adults with normal glucose tolerance, prediabetes and/or type 2 diabetes, demonstrated no effect of vitamin D supplementation on improving glucose homeostasis and preventing diabetes including only RCTs. Definitive conclusion could not be drawn in the context of heterogeneity, short-term follow-up duration and variable risk of bias (15) . Due to the ongoing increased interest in the effect of vitamin D on glycaemic control in type 2 diabetes, many more studies have been published since these meta-analyses were performed.
Taken together, it is still unclear whether vitamin D supplementation has a beneficial effect on glycaemic control in patients with type 2 diabetes mellitus. We present an up to date analysis of the effect of vitamin D supplementation on glycaemic indices (HbA 1c , insulin resistance and fasting glucose) in patients with type 2 diabetes mellitus.
Methods

Search strategy and selection criteria
A systematic literature search (MEDLINE, Embase and The Cochrane Library) was performed to identify articles from January 1976 to 15 October 2015 that assessed the effect of vitamin D supplementation on glycaemic indices in patients with type 2 diabetes. The search terms included type 2 diabetes mellitus AND (vitamin D OR vitamin D deficiency OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol). References of the retrieved articles were scanned for additional studies. The objective was to systematically review the evidence that vitamin D could improve glycaemic indices (HbA 1c , insulin resistance and fasting glucose) in patients with type 2 diabetes. One author (YK-P) performed an initial screening of titles and abstracts. Full-text articles of the selected titles were screened using the inclusion criteria described below. If there was a doubt to whether a particular article should be included, the author discussed the article with the last author (SS) until consensus was reached.
We included randomized controlled trials (RCT) in the following groups: vitamin D supplementation versus placebo, vitamin D supplementation and calcium supplementation versus calcium alone and/or placebo. Additional inclusion criteria were the following: (i) the study population consisted of patients with type 2 diabetes; (ii) supplementation of vitamin D 2 (ergocalciferol) or vitamin D 3 (cholecalciferol) for intervention; (iii) HbA 1c or parameters of glycaemic control (fasting glucose, fasting insulin or homeostatic model assessment -insulin resistance (HOMA-IR)) had to be a primary or secondary outcome; (iv) the authors report data of an original clinical study (i.e. no review, commentary, case reports, or editorial); (v) study performed in adults ≥18 years; (vi) published in English. We excluded studies carried out using 1,25-dihydroxyvitamin D and studies performed in patients other than type 2 diabetes mellitus, or patients on dialysis.
Quality assessment and data extraction
The quality of selected articles was assessed by two reviewers using a checklist from the Dutch Cochrane Collaboration (Fig. 1) (16) . The checklist consists of 11 criteria, with each criterion having three answer options: yes (adequate information/approach); no (no adequate information/approach); or little information. Each criteria answered with yes scored one point, we considered a total score ≥9 points as a good quality study.
Data were extracted by one author (YK-P) and controlled by the last author (SS) using a self-composed form including the following items of studies included: country, design, publication year, participants, therapy duration, type and dose of vitamin D supplementation, primary outcome, baseline and change in serum 25-hydroxy vitamin D (25(OH)D) and parameters of glycaemic control (HbA 1c, fasting glucose, fasting insulin and homeostasis model of assessment -insulin resistance (HOMA-IR)). For studies lacking a reported standard deviation of change in outcome between baseline and follow-up, we derived standard deviation of change as the mean of the baseline and follow-up standard deviations for each treatment group. This method was used successfully in the metaanalysis from George et al. performed on this subject (14) .
Statistical analysis
To obtain a summarized outcome of the effect of vitamin D supplementation on glycaemic control, we compared the mean change between baseline and follow-up of each variable of the intervention and control group. Studies in which the mean change and/or standard deviation was not reported, or could not be derived, were excluded from the meta-analysis. If a study included more than two groups, we used the data of the group in which the highest dose of vitamin D supplementation was given for the metaanalysis compared with placebo. If studies compared both vitamin D and/or calcium supplementation versus placebo, the data of the group with solely vitamin D supplementation were used for the meta-analysis.
The results of the included studies were pooled and meta-analyses were carried out using random-effects models, as some heterogeneity of outcome was expected. To compare the intervention and placebo groups, the results are presented as between-group standardized mean differences with 95% CI. Subgroup analyses were performed for studies with a baseline mean serum 25(OH)D <50 nmol/L and <30 nmol/L, and for studies having a mean baseline HbA 1c ≥8% (64 mmol/L) in the intervention group. We assessed statistical heterogeneity between studies with I 2 statistic (with 95% CIs). The I 2 is the proportion of total variation contributed by betweenstudy variation. In general, I 2 values greater than 60-70%
indicate the presence of substantial heterogeneity (17) . In the presence of heterogeneity between studies, we assessed potential publication bias using formal tests: the funnel plot and Egger test (18) . Meta-analyses were performed using comprehensive meta-analysis version 3.0 (http:// www.meta-analysis.com). A P value <0.05 was considered to be statistically significant.
Results
Selected articles
The initial systematic search yielded 1489 articles. Of those, 328 were duplicates and 1074 articles were excluded based on abstract and title. The most common reasons for exclusion of these articles were no inclusion of patients with type 2 diabetes or no intervention with vitamin D. Eighty-seven articles were selected for full-text review as shown in Fig. 2 Figure 1 Quality checklists randomized controlled trials (RCTs). 
Figure 2
Flow chart of literature search. 
Description of the studies
Twenty-three RCTs representing a total of 1797 patients with type 2 diabetes were included in this systematic review. The quality assessment of the studies resulted in 14 out of 23 studies having a good quality (Appendix 1, see section on Appendix given at the end of this article) (12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31) . The main characteristics and main outcomes of the included studies are given in Table 1 . All studies had a randomized controlled trial design, of which 18 studies used a placebo for control (12, 19, 20, 22, 23, 24, 25, 27, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38) , three studies compared vitamin D fortified yoghurt versus plain yoghurt (21, 28, 39) , one study used oral calcium supplementation for control (26) , and one study used vitamin C supplementation for control (40) . Apart from two studies, which solely included post-menopausal women (21, 33) , all studies included both men and women. Mean age varied from 44 to 67 years (24, 25 Favours control Favours vitamin D Figure 3 Mean change from baseline in serum 25(OH)D (nmol/L) between intervention and control. Based on a random-effect meta-analysis, comparing the mean change in HbA 1c from baseline between the intervention and placebo groups, no overall effect was seen on HbA 1c after vitamin D intervention (standardized difference in means: 0.12; 95% CI: −0.03 to 0.26, P = 0.11) (Fig. 4A) . Heterogeneity was present (I 2 = 42%, P = 0.03);
however, there was no evidence for publication bias (Egger's test: P = 0.38).
Including only the studies with a mean baseline 25(OH)D <50 nmol/L did not change the effect of vitamin D intervention on HbA 1c (standardized difference in means: 0.14; 95% CI: −0.07 to 0.35, P = 0.20) (Fig. 4B)  (12, 19, 22, 23, 25, 27, 28, 29, 30, 32, 34, 38, 39 ). In addition, no difference was seen, including only the studies with a mean baseline serum 25(OH)D <30 nmol/L (standardized difference in means: 0.02; 95% CI: −0.18 to 0.23, P = 0.82) (Fig. 4C) . Including the studies with a baseline mean HbA 1c ≥8% (64 mmol/mol) a trend towards a positive effect of vitamin D supplementation was seen, but this was not significant (standardized difference in means: 0.14; 95% CI: −0.05 to 0.33, P = 0.14) (Fig. 4D) .Furthermore, inclusion of the studies which were labelled as good quality did not alter the results (standardized difference in means: 0.01; 95% CI: −0.12 to 0.14, P = 0.90) (Fig. 5) . Heterogeneity was not present (I 2 = 1%).
The effect on fasting glucose
Of the 23 studies that were included in the systematic review, 13 reported fasting glucose as primary or secondary outcome measure (19, 20, 21, 22, 23, 24, 26, 27, 28, 32, 35, 36, 39) . Three studies reported a significant reduction in fasting glucose level after vitamin D supplementation (21, 28, 39) .
A pooled meta-analysis including 1180 patients (vitamin D: n = 608; controls: n = 572) comparing the mean change in fasting glucose between baseline and follow-up for both groups did not reveal an overall effect of vitamin D supplementation on fasting glucose (between-group standardized mean difference: 0.09; 95% CI: −0.11 to 0.28, P = 0.39, I 2 = 60%) (Fig. 6A) . No evidence for publication bias was found using a funnel plot and Egger's test (P = 0.97). Including only the good quality studies did not alter the effect on fasting glucose. A pooled meta-analysis with the inclusion of the studies with a mean baseline HbA 1c ≥8% (64 mmol/mol) shows a significant effect of vitamin D on fasting glucose (standardized difference in means: 0.36; 95% CI: 0.12-0.61, P = 0.003, I 2 = 0%) (Fig. 6B) .
The effect on insulin resistance
Thirteen studies reported data on insulin resistance, of which twelve studies used the HOMA-IR to quantify insulin resistance (19, 20, 21, 22, 24, 25, 26, 29, 30, 35, 36, 39) , and one study measured insulin resistance of vitamin D supplementation on insulin resistance compared with controls (between-group standardized difference in means: 0.23; 95% CI: −0.06 to 0.53, P = 0.12; I 2 = 77%, P = 0.04) (Fig. 7) . No evidence for publication bias was found using a funnel plot and Egger's test (P = 0.26). Inclusion of the studies which were qualified as good did not alter the results. Only one study reported data of HOMA-IR with a baseline HbA 1c ≥8%. The study performed by Kampmann et al. (23) , which measured insulin resistance by using the hyperinsulinaemiceuglycaemic clamp method -the golden standard -did not find a positive effect of vitamin D on glycaemic control in 16 patients with type 2 diabetes.
Discussion
Our The main challenge of this systematic review was the heterogeneity between the studies. To level for this challenge, we included only RCTs. However, still heterogeneity was present with a wide variety of intervention schemes and follow-up duration used in the studies included, which resulted in a varying increase in serum 25(OH)D as was shown in Fig. 2 . To resolve the problem of heterogeneity, we made a quality assessment of all included studies. Including only good quality studies did not alter the effect of vitamin D supplementation on glycaemic indices.
Still no consensus has been reached in the optimal value of serum 25 A possible explanation for the lack of effect found in most studies could be an underrepresentation of vitamin D-deficient patients. It is possible that vitamin D could only be effective in vitamin D-deficient patients, and especially in those with poor glycaemic control (43, 44) . This hypothesis was confirmed in the study performed by Soric et al. (40) , who showed a 1.4% decrease in HbA 1c in patients with a baseline HbA 1c level ≥9.0% after 12 weeks with a daily consumption of 2.000 IU vitamin D in contrast to patients with a HbA 1c <9.0% where no effect on glycaemic control was seen after vitamin D treatment. Additionally, in our previous RCT among 275 patients with type 2 diabetes, in 19 patients with a serum 25(OH) D below 30 nmol/L, a significant decrease in HbA 1c level was seen after 6 months of vitamin D supplementation compared with placebo (24) . Another important note is the wide range in follow-up duration between the studies. As HbA 1c is representing the glycosylated haemoglobin which has a lifetime around 100 days, a follow-up duration of more than three months is favourable. Favours control Favours vitamin D Figure 5 Meta-analysis of effects on HbA 1c in studies labelled as good quality. Meta-analysis of effects on fasting glucose in all studies (A) and in studies with a baseline mean HbA 1c ≥8% (B).
Model
Individual variability explained by vitamin D receptor polymorphisms may also play a role in the study results. Earlier research demonstrated an association between vitamin D receptor polymorphisms and the risk for type 2 diabetes, suggesting that timing of vitamin D supplementation is critical (46, 47) . In addition, a study by Wang et al. demonstrated that the vitamin D-binding protein polymorphism, and thus vitamin D bioavailability, was moderately associated with increased susceptibility to type 2 diabetes in Asians, but not in Caucasians, suggesting that ethnicity might be a potential factor associated with heterogeneity (48) .
Another relevant note is the different vitamin D assays that were used in the included studies. Much discussion is going on about the comparability and accuracy of the different assays, which raises concerns (49) . Most of the studies included in this review used an enzyme-immunoassay method for measurement of serum 25(OH)D, where the liquid chromatography--mass spectrometry (LC-MS) method is the golden standard.
The strength and limitations of our study need to be mentioned. First, as our initial search was performed by only one author, all eligible studies may not have been included. However, our negative findings suggest that unpublished studies (which also tend to be negative) would be very unlikely to alter our conclusions. We found no evidence for publication bias from the funnel plots. For the meta-analysis, we performed a quality assessment according to the checklist of the Dutch Cochrane Collaboration, which has some limitations, especially when trying to decide on the relative importance of the different criteria (16) . Another note is that we did not have access to all original data, which is the best method to perform a meta-analysis. A strength of our study is that we included only RCTs to assess the strength of evidence and limit the role of bias.
In conclusion, current evidence of RCTs does not support short-term vitamin D supplementation in a heterogeneous population with type 2 diabetes. However, in patients with poorly controlled diabetes a favourable effect of vitamin D is seen on fasting glucose. Future research in this subgroup is highly of interest.
Appendix
This is linked to the online version of the paper at http://dx.doi.org/10.1530/ EJE-16-0391.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
Model Study name
Sample size S td di in means and 95% Cl Favours control Favours vitamin D Figure 7 Meta-analysis of effects on HOMA-IR.
